Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2017-03-20 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
2016年年度报告摘要
Annual Report Classification · 95% confidence The document is titled "深圳信立泰药业股份有限公司 2016 年年度报告摘要" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2016 Annual Report Summary." It contains detailed financial data for the year 2016, including revenue, profit, earnings per share, and other financial metrics. It also includes sections on company business overview, R&D activities, sales, governance, and shareholder information. The document is about 15,000 characters long, which is substantial and contains actual financial data and analysis. The content matches the characteristics of an Annual Report (10-K) rather than a brief summary or announcement. Therefore, this document should be classified as an Annual Report (10-K). FY 2016
2017-03-20 Chinese
关于举行2016年年度报告网上说明会的公告
AGM Information Classification · 95% confidence The document is a short announcement about holding an online explanation meeting for the 2016 annual report. It specifies the date and time of the meeting and invites investors to participate. It does not contain the annual report itself or detailed financial data, but rather informs about a presentation related to the annual report. The document length is only 460 characters, indicating it is a brief notice. According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is AGM Information (AGM-R), as it relates to materials shared during an annual general meeting or similar shareholder meeting event.
2017-03-20 Chinese
独立董事关于公司有关事项所发表的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from the independent directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding several company matters for the fiscal year 2016, including the profit distribution plan, remuneration of directors and senior management, internal control self-evaluation report, and external guarantees and related party fund occupation. It references compliance with relevant laws and regulations and provides independent opinions on these matters. The document is not a full annual report or financial statement but rather an independent directors' opinion letter on specific company governance and financial matters. It does not contain comprehensive financial data or detailed financial statements. This type of document is typically classified as a Regulatory Filing (RNS) because it is a compliance-related statement and independent opinion rather than a full report or announcement of voting results or remuneration details.
2017-03-20 Chinese
关于全资子公司与惠州大亚湾区政府置换土地使用权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xilintai Pharmaceutical Co., Ltd. regarding a land use rights swap transaction between its wholly-owned subsidiary and the Huizhou Daya Bay District government. It details the transaction overview, parties involved, asset descriptions, board approval, and the impact on the company. There are no financial statements or comprehensive financial performance data included. The document is a formal disclosure of a corporate transaction (land swap) and does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive transaction details. The content aligns with a Capital/Financing Update as it involves asset exchange and cash compensation affecting the company's capital assets and cash flow. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-03-20 Chinese
2016年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2016年度监事会工作报告" which translates to the "2016 Supervisory Board Work Report". It details the supervisory board's activities during the year 2016, including oversight of financial reports such as quarterly, half-year, and annual reports. It references the audit report issued by an accounting firm and discusses internal controls, financial supervision, and compliance with laws and regulations. The document is a comprehensive report on the supervisory board's work and oversight for the year, not just an announcement or a brief summary. It contains substantive content about the supervisory board's review and opinions on the company's financial and operational matters for the year 2016. This aligns with the category of an Audit Report / Information (AR), which includes audit reports and supervisory board reports related to internal controls and financial oversight, distinct from the full Annual Report (10-K). The document length (3485 characters) is relatively short but contains detailed supervisory content rather than just a notice or announcement, so it is not an RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2016
2017-03-20 Chinese
2016年度独立董事述职报告（李中军）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for the Year 2016" from Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, participation in committees, supervision of internal controls and information disclosure, and other duties performed during the year. The content is a narrative report on the director's activities and responsibilities rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings. It is a management-related report focusing on board activities and governance oversight by an independent director. Therefore, the document best fits the category of Board/Management Information (MANG). The document length is 2594 characters, which is consistent with a detailed report but not a full annual report or audit report. No indication of voting results, capital changes, or legal proceedings is present.
2017-03-20 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.